Innate Pharma : A new transformative deal with Astrazeneca: Buy vs Neutral
>Asset swap with AstraZeneca: Innate will start to market products! - This morning, Innate Pharma has announced a new transformative deal with its partner Astrazeneca. Under the terms of the agreement: 1/ Innate acquires the sales rights for Lumoxiti in the US and Europe (moxetumomab pasudotox-tdfk), a treatment for HC leukemia – a rare disease with around 1000 cases per year in the US. This treatment is developed by AstraZeneca and was approved by the FDA on 13 Septe...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.